Mesenchymal stem cell therapy (Longeveron)

🔵 卷首语：衰老不再“听天由命”，药物级抗衰，真的来了 当年龄增长、体力下滑、步履变慢、易累易乏、肌肉流失、免疫力下降——老年衰弱，正困扰全球1/4的50岁以上人群，也是跌倒、失能、慢病加速的核心元凶。 长期以来，衰老与衰弱只能“调养、补剂、被动应对”，无特效药、无靶向方案、无标准化干预。直到2026年2月，《Nature》《Science》联合刊发全球首个干细胞抗衰新药II期临床完整数据：单次静脉注射干细胞药物，9个月后衰弱老人体能提升22%，六分钟步行距离增加63米，衰弱等级逆转一级，安全无严重不良反应。 这不是医美噱头、不是保健概念，是通过FDA严格临床试验、随机双盲安慰剂对照、可量化、可重复、可落地的药物级再生医学突破。全球首款针对“衰老衰弱”的干细胞新药，距离正式获批上市，只剩最后一步。 今天，用最严谨、最通俗、最干货的解读，带你看懂这场人类抗衰史上的里程碑革命。 临床硬核数据：一针见效，9个月体能+22%，不是虚标 📌 试验基本信息（权威可查） ①研发企业：美国Longeveron（全球领先再生医药公司） ②药物名称：Laromestrocel（异体骨髓间充质干细胞注射液） ③试验设计：随机、双盲、安慰剂对照（医学界最高证据等级） ④入组人群：148位70-85岁确诊衰弱、可自主行走老人 ⑤干预方式：单次静脉注射，无需多次、无需长期疗程 ⑥观察周期：9个月（长期稳定随访，无短期“一过性效果”）  核心结果，震撼全球医学界 1. 体能核心指标暴涨 最高剂量组：六分钟步行距离平均增加63.4米，相对基线体能提升22%，与安慰剂组差异统计学极显著。 2. 衰弱等级直接逆转 临床衰弱量表（CFS）整体提升1个等级，部分老人彻底脱离“衰弱”判定，回归健康老年状态。 3. 全身功能同步改善 肌力、平衡、日常活动能力、疲劳感、睡眠质量、自评健康分数（PROMIS）全面上涨，生活半径显著扩大。 4. 安全性拉满 无严重免疫排斥、无严重感染、无致瘤风险、无长期不良反应，老年体弱人群耐受度极佳。 加拿大老年病学权威、衰弱量表发明人Kenneth Rockwood教授直言：“衰弱等级提升一级，在老年医学中极难实现，这个数据是颠覆性的。” 为什么它能“逆转衰老”？干细胞抗衰的底层逻辑 很多人疑惑：干细胞不是“新细胞替换”吗？为什么一针能管9个月？ 这款新药的核心，是异体间充质干细胞（MSC）的“系统性修复能力”，不靠“换细胞”，靠“修环境、控炎症、激活自愈”。 ✅ 三大核心作用机制（科学通俗版） 1. 压制“衰老元凶”：慢性低度炎症 清除TNF-α、IL-6等促炎因子，降低全身“炎性衰老”，从根源减缓器官与肌肉退化。 2. 修复血管与微循环，恢复供血供能 改善内皮功能，提升肌肉与脏器血氧与营养供给，走路更稳、更久、更有力。 3. 旁分泌修复：激活自体干细胞，重启再生 分泌外泌体、生长因子、细胞信号分子，唤醒身体自身修复力，实现长效年轻化稳态。 简单说：它不是“临时补能”，是把衰老的身体“底层系统”重装一遍，从炎症、血管、代谢、肌肉、免疫全方位回春。 关键区分：这是“药品”，不是医美、不是保健、不是野针 ⚠️ 重要提醒：本次突破是药监申报的新药，和市面上天价“干细胞抗衰针”完全两回事！ 🧾 正规新药VS乱象项目，一眼看懂 🟩 正规干细胞新药（Laromestrocel） 药监申报、III期在即、严格临床试验 标准化制备、GMP质控、剂量精准、全程可追溯 适应症明确：老年衰弱综合征（医学诊断，非美容抗衰） 数据公开、期刊发表、专家共识、安全可控 🟥 非正规“抗衰针”（警惕踩坑） 无批文、无临床、无标准、无剂量 包装“逆龄、除皱、长生”，夸大宣传 细胞来源不明、活率未知、风险不可控 价格虚高，无疗效保障，违规操作 本次突破的最大意义：抗衰正式进入“药物化、合规化、标准化、普惠化”时代，告别野蛮生长。 全球同步冲刺：中国干细胞抗衰，也迎来黄金时代 不止海外，中国干细胞新药研发正全速推进，多项临床数据同样亮眼： 国内获批干细胞抗衰/衰弱临床超200项，位居全球前列 国产脐带MSC临床：6个月步行距离提升≥15%，炎症因子下降30%-40% 国家药监局818/828号令落地，规范细胞治疗，合规药品将快速上市 未来2-3年，国内外多款干细胞抗衰/衰弱新药将密集获批，从“罕见高端疗法”变成常规临床干预方案，百岁健康、老而不衰，不再是梦想。 适用人群：谁能受益？不是所有人都适合（严谨科普） ✅ 最适配人群（新药核心目标） ①70岁以上，确诊老年衰弱综合征 ②走路慢、易累、肌力下降、平衡差、易跌倒 ③慢性疲劳、睡眠差、免疫力低、反复感染 ④慢病共存（高血压、糖尿病、骨关节退变）伴体能衰退 ❌ 暂不适用/不推荐 ①健康年轻人、单纯想“美容抗衰、除皱”（无适应症，不获益） ②晚期肿瘤、严重感染、凝血障碍、严重免疫疾病 ③孕期、哺乳期人群 核心定位：治疗衰弱、提升体能、改善生活质量、降低失能风险，是医学治疗，不是“美容针”。 上市时间与未来：多久能用到？价格会亲民吗？ ⏳ 上市进度 ①已完成II期临床，数据优异，安全性与有效性双验证 ②正在推进III期确证试验（扩大样本、长期随访） ③乐观预期：18-24个月内，有望获FDA批准上市，成为全球首款抗衰干细胞药。 💰 价格与可及性 ①初期为处方药，定价会高于普通药物，但远低于当前天价私立项目 ②随着量产、国产化、医保准入推进，未来逐步普惠，普通家庭可承受 ③国内同类药物同步研发，未来将形成“国际+国产”双供给，价格更友好。 行业启示：抗衰进入“细胞药物时代”，三大趋势已定 1. 从“保养”到“治疗”：衰老衰弱成为正式疾病，有药可治、有方可依。 2. 从“经验”到“精准”：剂量标准化、个体化给药、疗效可量化、安全可保障。 3. 从“小众”到“大众”：合规监管+产业成熟，再生医学走进千家万户。 过去，我们对抗衰老，只能束手无策； 现在，药物逆转衰老、科学延长健康寿命，已经从科幻走进现实。 健康长寿，从“被动衰老”到“主动干预” 一针干细胞，9个月体能+22%，衰弱逆转，安全可控——这不是终点，是人类健康长寿的全新起点。 会诊CGT始终紧跟全球前沿，聚焦合规细胞药物、智能精准处方、全流程安全管控，致力于让每一位朋友都能享受到科学、安全、有效、可及的再生医学红利，老而不衰、病而不残、健享长寿。 衰老不可避免，但衰弱可以逆转、体能可以恢复、生活质量可以重塑。未来已来，药物级抗衰时代，正式开启。 🔹 关注我们，第一时间获取干细胞新药上市动态 🔹 后台回复【抗衰评估】，免费获取衰弱风险自测+专业咨询 🔹 转发本文，让家人朋友远离抗衰骗局，拥抱科学长寿。 一次自体NK细胞输注，四周后衰老T细胞减少40%！ 301医院干细胞服务，为你健康保驾护航

MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the Cell Stem Cell website here. Laromestrocel (LOMECEL-B®) is a proprietary, scalable, allogeneic stem cell (MSC) investigational therapy that is currently being evaluated in multiple indications. “We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” said Joshua M. Hare, MD, FACC, FAHA, Chief Science Officer at Longeveron. “Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery. This development area is at the core of Longeveron’s mission – advancing stem cell therapies addressing life threatening conditions in the most vulnerable populations - children and the elderly.” The Phase 2b, randomized, dose-finding clinical trial evaluated whether laromestrocel, human bone marrow-derived allogeneic MSCs, improves physical functioning and patient self-reported outcomes in 148 ambulatory individuals with frailty (NCT03169231). Laromestorcel infusions resulted in: Clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test (6MWT) compared with placebo: 63.4m (95% confidence interval [CI]: 17.1-109.6m; p=0.0077) at month 9 and 41.3m (95% CI: -2.4-84.9m; p=0.0635) at month 6 Increased 6MWT distance correlates with PROMIS Physical Function score Increasing doses of laromestrocel are associated with decreases in soluble (degraded) tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (TIE-2), the cognate receptor for the angiopoietins, identifying a potential biomarker for laromestrocel responsiveness These findings identify a possible stem cell therapy approach for the management of patients with hypomobility and other features of aging frailty. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram. Forward-Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the future restoration of executive compensation levels; our intention and ability to repay certain compensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investor and Media Contact: Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc